Nicorette 2 mg and 4 mg cleared for OTC use by FDA advisory committee.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM NICORETTE Rx-TO-OTC SWITCH RECOMMENDED FOR APPROVAL at a joint meeting of FDA's Nonprescription Drugs and Drug Abuse Advisory Committees on Sept. 28. The joint committee unanimously agreed that the product is "safe and effective for self-medication when used as directed" at both 2 and 4 mg doses.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning